Kairos Pharma, LTD.

Develops novel oncology therapies to reverse drug resistance and immune suppression.

KAPA | US

Overview

Corporate Details

ISIN(s):: US48301N1046
LEI:
Country:: United States of America
Address:: 2355 WESTWOOD BLVD. #139, 90064 LOS ANGELES
Website:: https://kairospharma.com
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kairos Pharma, LTD. is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for cancer patients. The company focuses on addressing two critical hurdles in oncology: overcoming resistance to cancer drugs and reversing cancer-induced immune suppression. Its lead candidate, ENV105, is an antibody designed to reverse drug resistance by targeting the CD105 protein; it is currently in Phase 2 trials for prostate cancer and Phase 1 for lung cancer. Kairos Pharma's immunotherapy pipeline includes KROS101, a small molecule to enhance T cell response, and KROS201, a T cell therapy targeting cancer stem cells in glioblastoma. The company's innovative approach aims to restore the efficacy of standard treatments and reactivate the patient's immune system to fight cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Kairos Pharma, LTD. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kairos Pharma, LTD.

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Kairos Pharma, LTD. via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
KOLON LIFE SCIENCE Inc. Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.	South Korea	102940
Kolon TissueGene, Inc. Developing cell and gene therapies for orthopedic and degenerative disorders.	United States of America	950160
KOMIPHARM INTERNATIONAL CO., LTD. Develops animal health products and novel drugs for human cancer and autoimmune diseases.	South Korea	041960
KOREA ARLICO PHARM CO.,LTD. Manufactures generic drugs and provides CDMO services to a global market.	South Korea	260660
KOREAN DRUG CO., LTD. Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.	South Korea	014570
Korro Bio, Inc. A clinical-stage biopharma using RNA editing to develop medicines for rare & prevalent diseases.	United States of America	KRRO
K Pharma,Inc. Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.	Japan	4896
Kringle Pharma,Inc. Develops regenerative HGF medicines for rare and intractable neurological diseases.	Japan	4884
Krka Develops and sells generic prescription, non-prescription, and animal health products globally.	Slovenia	KRKG
Krystal Biotech, Inc. Developing redosable gene therapies for rare diseases using a modified HSV-1 vector.	United States of America	KRYS